Review examines psoriasis, smoking linkA recent paper sheds light on the relationship between smoking and psoriasis. Results offer a whole scenario related to the impact of smoking on psoriasis.
Payers want more dataA pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
Diet, skin disease data growingA growing number of studies suggest diet influences general skin health and specific skin diseases, from acne and eczema to skin aging. Dermatologists share their best practices for using diet to combat skin disease and promote skin health.
Pediatric psoriasis prognosis, management insightsRelationships between pediatric psoriasis and streptococcal infection, obesity, and genetics are discussed for their relevance to patient care.
Common questions about biologicsMark Lebwohl, M.D., reviews evidence pertaining to malignancy risks with biologics and the rationale for avoiding “drug holidays”.
Controlling complicated psoriasisPatients with psoriasis who have medical co-morbidities or difficult-to-treat phenotypes may require special consideration for treatment selection.
Psoriasis topicals continue to fill pipelineOptions for topical treatment of psoriasis continue to expand with the development of products featuring novel vehicles or new molecules. Active research addresses this need.
FDA approves ixekizumab for plaque psoriasisThe FDA approved Taltz (ixekizumab, Eli Lilly and Company) injection 80 mg/mL March 22 for treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Learn more